Page 34 - Read Online

Allen et al. Hepatoma Res 2021;7:73 https://dx.doi.org/10.20517/2394-5079.2021.98 Page 13 of 15

10. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the
rise. Oncologist 2016;21:594-9. DOI PubMed PMC
11. Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol
2019;71:104-14. DOI PubMed
12. Petrick JL, Yang B, Altekruse SF, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a
population-based study in SEER-medicare. PLoS One 2017;12:e0186643. DOI PubMed PMC
13. Kanthan R, Senger JL, Ahmed S, Kanthan SC. Gallbladder cancer in the 21st century. J Oncol 2015;2015:967472. DOI PubMed
PMC
14. Tewari M, Agarwal A, Mishra RR, Meena RN, Shukla HS. Epigenetic changes in carcinogenesis of gallbladder. Indian J Surg Oncol
2013;4:356-61. DOI PubMed
15. Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing
mutations. J Hepatol 2018;68:959-69. DOI PubMed
16. Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am
Soc Clin Oncol Educ Book 2016;35:e194-203. DOI PubMed
17. Goldstein D, Lemech C, Valle J. New molecular and immunotherapeutic approaches in biliary cancer. ESMO Open 2017;2:e000152.
DOI PubMed PMC
18. Crispo F, Pietrafesa M, Condelli V, et al. IDH1 targeting as a new potential option for intrahepatic cholangiocarcinoma treatment-
current state and future perspectives. Molecules 2020;25:3754. DOI PubMed PMC
19. Ahn S, Lee JC, Shin DW, Kim J, Hwang JH. High PD-L1 expression is associated with therapeutic response to pembrolizumab in
patients with advanced biliary tract cancer. Sci Rep 2020;10:12348. DOI PubMed PMC
20. Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol
2020;12:693-708. DOI PubMed PMC
21. Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: a comprehensive literature review. Cancer Treat Res Commun
2021;27:100354. DOI PubMed
22. Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov
2017;7:943-62. DOI PubMed PMC
23. Belkouz A, Wilmink JW, Haj Mohammad N, et al. Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical
evidence based on phase II and III trials. Crit Rev Oncol Hematol 2020;151:102975. DOI PubMed
24. Personeni N, Lleo A, Pressiani T, et al. Biliary tract cancers: molecular heterogeneity and new treatment options. Cancers (Basel)
2020;12:3370. DOI PubMed PMC
25. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI PubMed
26. Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised
trials. Ann Oncol 2014;25:391-8. DOI PubMed
27. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a
comparative multicentre study in Japan. Br J Cancer 2010;103:469-74. DOI PubMed PMC
28. Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract
cancer. JAMA Oncol 2020;6:888-94. DOI PubMed PMC
29. Kang J, Jeong JH, Hwang HS, et al. Efficacy and safety of pembrolizumab in patients with refractory advanced biliary tract cancer:
tumor proportion score as a potential biomarker for response. Cancer Res Treat 2020;52:594-603. DOI PubMed PMC
30. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite
instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1-10. DOI
PubMed PMC
31. Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from
the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 2020;147:2190-8. DOI PubMed
32. Klein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced
biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol 2020;6:1405-9. DOI PubMed PMC
33. van Vugt JLA, Gaspersz MP, Coelen RJS, et al. The prognostic value of portal vein and hepatic artery involvement in patients with
perihilar cholangiocarcinoma. HPB (Oxford) 2018;20:83-92. DOI PubMed
34. Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma.
World J Surg 2018;42:2910-8. DOI PubMed
35. Kato A, Shimizu H, Ohtsuka M, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced
biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 2013;20:318-24. DOI PubMed
36. Le VH, O'Connor VV, Li D, Melstrom LG, Fong Y, DiFronzo AL. Outcomes of neoadjuvant therapy for cholangiocarcinoma: a
review of existing evidence assessing treatment response and R0 resection rate. J Surg Oncol 2021;123:164-71. DOI PubMed
37. Yeh CN, Hsieh FJ, Chiang KC, et al. Clinical effect of a positive surgical margin after hepatectomy on survival of patients with
intrahepatic cholangiocarcinoma. Drug Des Devel Ther 2015;9:163-74. DOI PubMed PMC
38. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-
analysis. J Clin Oncol 2012;30:1934-40. DOI PubMed
39. Takada T, Amano H, Yasuda H, et al; Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is
postoperative adjuvant chemotherapy useful for gallbladder carcinoma? Cancer 2002;95:1685-95. DOI PubMed